Burden of Autoimmune Disorders; A Review
Kimberly Morton Cuthrell *
Saint James School of Medicine, United States.
Nikolaos Tzenios
Public Health and Medical Research, Charisma University, Grace Bay, Turks and Caicos Islands.
Javeria Umber
Government College University Faisalabad (GCUF), Pakistan.
*Author to whom correspondence should be addressed.
Abstract
When immunologic tolerance to auto-reactive immune cells is lost, autoimmune illness manifests as the immune system attacking self-molecules. Numerous autoimmune diseases are strongly predisposed by genetic, viral, and/or environmental factors. Autoimmune diseases include insulin-dependent diabetic mellitus, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, thyroiditis, and multiple sclerosis. These autoimmune diseases are characterized by a variety of problems and symptoms that range from organ-specific to systemic. Autoimmune pathology may have a role in conditions like arteriosclerosis, inflammatory bowel disease, schizophrenia, and specific forms of infertility. This review consists of a brief explanation and analysis of the immune system and tolerance maintenance, a few autoimmune disorders, immune auto-reactivity mechanisms, and experimental autoimmune models.
Keywords: Autoimmune disease, systemic autoimmune diseases, B- cell tolerance, T- cell tolerance, immunosuppressive/immunocompromised disorders
How to Cite
Downloads
References
Invernizzi P, et al. Female predominance and X chromosome defects in autoimmune diseases. J Autoimmun. 2009;33(1):12-6.
Talal N. Sjögren's syndrome: historical overview and clinical spectrum of disease. Rheum Dis Clin North Am. 1992;18(3):507-15.
Fessel WJ. Systemic lupus erythematosus in the community. Incidence, prevalence, outcome, and first symptoms; the high prevalence in black women. Arch Intern Med. 1974;134(6):1027-35.
Linos A, et al. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am J Epidemiol. 1980;111(1):87-98.
Gartler SM, Riggs AD. Mammalian X-chromosome inactivation. Annu Rev Genet. 1983;17:155-90.
Willard HF. Tales of the Y chromosome. Nature. 2003;423(6942):810-1,813.
Plath K, et al. Role of histone H3 lysine 27 methylation in X inactivation. Science. 2003;300(5616):131-5.
Syrett CM, et al. Altered X-chromosome inactivation in T cells may promote sex-biased autoimmune diseases. JCI Insight. 2019;4(7).
McCain J. The disease burden of the most common autoimmune diseases. Manag Care. 2016;25(7):28-32.
Cooper GS, Miller FW, Germolec DR. Occupational exposures and autoimmune diseases. International Immunopharmacology. 2002;2(2):303-313.
Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmunity Reviews. 2003;2(3):119-125.
Eaton WW, et al. Epidemiology of autoimmune diseases in Denmark. J Autoimmun, 2007;29(1):1-9.
Walsh SJ, Rau LM. Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States. Am J Public Health. 2000;90(9):1463-6.
Kong MF, Jeffcoate W. Eighty-six cases of Addison's disease. Clin Endocrinol (Oxf). 1994;41(6):757-61.
Yu C, Gershwin ME, Chang C. Diagnostic criteria for systemic lupus erythematosus: A critical review. Journal of Autoimmunity. 2014;48-49:10-13.
Laakso M, et al. Death certificate and mortality in rheumatoid arthritis. Scand J Rheumatol. 1986;15(2):129-33.
Calvo-Alén J, et al. Lack of recording of systemic lupus erythematosus in the death certificates of lupus patients. Rheumatology (Oxford). 2005;44(9):1186-9.
Mühlhauser I, et al. Reliability of causes of death in persons with Type I diabetes. Diabetologia. 2002;45(11):1490-7.
Broadley SA, et al. Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain. 2000;123 ( Pt 6):1102-11.
Cooper GS, et al. The prevalence and accuracy of self-reported history of 11 autoimmune diseases. J Rheumatol, 2008;35(10):2001-4.
Anaya JM, Gómez L, Castiblanco J. Is there a common genetic basis for autoimmune diseases? Clin Dev Immunol. 2006;13(2-4):185-95.
Cohen R, et al. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm Bowel Dis. 2008;14(6):738-43.
Somers EC, et al. Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder? Am J Epidemiol. 2009;169(6):749-55.
Kyurkchiev D, et al. Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J Stem Cells, 2014;6(5):552-70.
Ren, G, et al, Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol, 2010;184(5):2321-8.
Jiang D, et al. Suppression of neutrophil-mediated tissue damage-a novel skill of mesenchymal stem cells. Stem Cells. 2016;34(9):2393-406.
Ryan, S.T, et al, Extracellular Vesicles from Mesenchymal Stromal Cells for the Treatment of Inflammation-Related Conditions. Int J Mol Sci, 2021;22(6).
Maccario R, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 2005;90(4):516-25.
Wang L, et al. Breach of Tolerance: Primary Biliary Cirrhosis. Semin Liver Dis. 2014;34(03):297-317.
Silverstein AM, Paul Ehrlich. Archives and the history of immunology. Nature Immunology. 2005;6(7):639-639.
Rose NR, Witebsky E. Studies on organ specificity. V. Changes in the thyroid glands of rabbits following active immunization with rabbit thyroid extracts. J Immunol. 1956;76(6):417-27.
Salinas GF, et al. The role of B lymphocytes in the progression from autoimmunity to autoimmune disease. Clinical Immunology. 2013;146(1):34-45.
Hang L, Nakamura RM, Tubbs R. Current concepts and advances in clinical laboratory testing for autoimmune diseases. Critical Reviews in Clinical Laboratory Sciences. 1997;34(3):275-311.
Khan U, Ghazanfar H. T lymphocytes and autoimmunity. Int Rev Cell Mol Biol. 2018;341:125-168.
Simpson E. Function of the MHC. Immunol Suppl. 1988;1:27-30.
Wu D, et al. Prevalence of Type 1 diabetes in New Zealanders aged 0-24 years. N Z Med J. 2005;118(1218):U1557.
Moore KR, et al. Three-year prevalence and incidence of diabetes among American Indian youth in Montana and Wyoming, 1999 to 2001. J Pediatr. 2003;143(3):368-71.
Peter SA, et al. The incidence and prevalence of type-1 diabetes mellitus. J Natl Med Assoc. 2005;97(2):250-2.
Al-Herbish AS, et al. Prevalence of type 1 diabetes mellitus in Saudi Arabian children and adolescents. Saudi Med J. 2008;29(9):1285-8.
Moussa, M.A, et al, Prevalence of type 1 diabetes among 6- to 18-year-old Kuwaiti children. Med Princ Pract. 2005;14(2):87-91.
Boberg KM, et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol, 1998;33(1):99-103.
Hurlburt KJ, et al. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol. 2002;97(9):2402-7.
Lee YM, et al. Autoimmune hepatitis in Singapore: a rare syndrome affecting middle-aged women. J Gastroenterol Hepatol. 2001;16(12):1384-9.
Rautiainen H, et al, Prevalence and incidence of primary biliary cirrhosis are increasing in Finland. Scand J Gastroenterol. 2007;42(11):1347-53.
Taussig MJ. Molecular genetics of immunoglobulins. Immunol Suppl. 1988;1:7-15.
Nemazee, D, Mechanisms of central tolerance for B cells. Nat Rev Immunol. 2017;17(5):281-294.
Rose NR. Mechanisms of autoimmunity. Semin Liver Dis. 2002;22(4):387-94.
Kim WR, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology. 2000;119(6):1631-6.
James OF, et al. Primary biliary cirrhosis once rare, now common in the United Kingdom? Hepatology.1999;30(2):390-4.
Delgado J, et al. The epidemiology of primary biliary cirrhosis in southern Israel. Isr Med Assoc J. 2005;7(11):717-21.
Hollowell JG, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489-99.
Mayr WT, et al, Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology. 2003;61(10):1373-7.
Hader WJ, Yee IM. Incidence and prevalence of multiple sclerosis in Saskatoon, Saskatchewan. Neurology. 2007;69(12):1224-9.
Warren SA, Svenson LW, Warren KG. Contribution of incidence to increasing prevalence of multiple sclerosis in Alberta, Canada. Mult Scler. 2008;14(7):872-9.
Svenson LW, et al. Prevalence of multiple sclerosis in First Nations people of Alberta. Can J Neurol Sci. 2007;34(2):175-80.
Kuehn HS, et al. FAS haploinsufficiency is a common disease mechanism in the human autoimmune lymphoproliferative syndrome. J Immunol. 2011;186(10):6035-43.
Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: a comprehensive update. Journal of Internal Medicine. 2015;278(4):369-395.
Prevalence of Autoimmune Diseases - Autoimmune Disease _ Johns Hopkins Pathology.pdf.
Päivönsalo-Hietanen T, Tuominen J, Saari KM. Uveitis in children: population-based study in Finland. Acta Ophthalmol Scand. 2000;78(1):84-8.
Stephen C. Capture-recapture methods in epidemiological studies. Infect Control Hosp Epidemiol. 1996;17(4):262- 6.
Ginn LR, et al. Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases. Arthritis Rheum. 1998;41(3):400-5.
Anaya JM, et al. Autoimmune disease aggregation in families with primary Sjögren's syndrome. J Rheumatol. 2006; 33(11):2227-34.
Dandona L, et al. Population based assessment of uveitis in an urban population in southern India. Br J Ophthalmol. 2000;84(7):706-9.
Gershwin ME, Bone marrow transplantation, refractory autoimmunity and the contributions of Susumu Ikehara. J Autoimmun. 2008;30(3): 105-7.
Whittingham S, Rowley MJ, Gershwin ME. A tribute to an outstanding immunologist - Ian Reay Mackay. J Autoimmun. 2008;31(3):197-200.
Mackay IR, Leskovsek NV, Rose NR. Cell damage and autoimmunity: a critical appraisal. J Autoimmun. 2008;30(1-2):5-11.
Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110-21.
Rose NR, Neumann DA, Herskowitz A. Autoimmune myocarditis: concepts and questions. Immunol Today. 1991; 12(8):253-5.
Lieberman EB, et al. Clinicopathologic description of myocarditis. J Am Coll Cardiol. 1991; 18(7):1617-26.
Rose NR. Autoimmunity in coxsackievirus infection. Curr Top Microbiol Immunol. 2008;323: 293-314.
Rashtak S, Pittelkow MR. Skin involvement in systemic autoimmune diseases. Curr Dir Autoimmun. 2008;10:344-58.
Shoenfeld Y, et al. The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun. 2008;31(4):325-30.
Rongioletti F, et al. Scleroderma with an update about clinico-pathological correlation. G Ital Dermatol Venereol. 2018;153(2):208-215.
Llanos O, Hamzeh N. Sarcoidosis. Med Clin North Am. 2019;103(3):527-534.
Lebwohl B, Sanders DS, Green PHR. Coeliac disease. Lancet. 2018;391(10115):70-81.
Alkhateeb A, et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res. 2003;16(3):208-14.
Somers EC, et al. Autoimmune diseases co-occurring within individuals and within families: a systematic review. Epidemiology. 2006;17(2):202-17.
Lettre G, Rioux JD. Autoimmune diseases: insights from genome-wide association studies. Hum Mol Genet. 2008;17(R2):R116-21.
Cushing K, Higgins PDR. Management of crohn disease: A review. Jama. 2021;325(1):69-80.
Miyamoto D, et al. Bullous pemphigoid. An Bras Dermatol. 2019;94(2):133-146.
Zhu W, et al. Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res. 2019; 7:22.
Ömerhoca S, Akkaş SY, İçen NK. Multiple Sclerosis: Diagnosis and Differential Diagnosis. Noro Psikiyatr Ars. 2018;55(Suppl 1):S1-s9.
Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16(3):145-154.
Hardy RS, Raza K, Cooper MS. Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases. Nat Rev Rheumatol. 2020;16(3):133-144.
Nikiphorou E, Buch MH, Hyrich KL. Biologics registers in RA: Methodological aspects, current role and future applications. Nat Rev Rheumatol. 2017;13(8):503-510.
Rendas-Baum R, et al. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors. Arthritis Res Ther. 2011;13(1):R25.
Kuijper TM, et al. Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: A systematic review. J Rheumatol. 2015;42(11):2012-22.
Murphy G, Isenberg DA. New therapies for systemic lupus erythematosus - past imperfect, future tense. Nat Rev Rheumatol. 2019; 15(7): 403-412.
Mosanya CH, Isaacs JD. Tolerising cellular therapies: what is their promise for autoimmune disease? Ann Rheum Dis. 2019;78(3):297-310.
Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-7.
Wang Y, et al. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol. 2014;15(11):1009-16.